Legislative updates in Mississippi, West Virginia, Oregon, and New Hampshire plus federal and legal psychedelics news

Ibogaine and psilocybin policy moves in multiple US states, while federal and legal developments affect how psychedelic medicines may advance. Mississippi's ibogaine bill (SB 2561) fails to advance from a Senate committee after the state House passed it overwhelmingly. West Virginia’s ibogaine bill (HB 4626) passes the House and heads to the Senate Health and Human Resources Committee, proposing research funding via a public-private partnership. Oregon introduces an ibogaine bill (HB 4110) that would allow physician-provided ibogaine for conditions including PTSD and major depressive disorder, with an exemption from the state’s controlled substance definition. New Hampshire rejects one detailed psilocybin program proposal (HB 1796) while advancing another with fewer specifics (HB 1809). Federally, the US Food and Drug Administration’s fast-track voucher plan for Compass’s synthetic psilocybin COMP360 reportedly gets vetoed, delaying the expected path to an FDA decision. A federal bill proposes VA research and extended access for psychedelic- and entactogen-assisted therapies for veterans, and Definium (formerly MindMed) faces a trade secret lawsuit involving its LSD formulation MM120 trial work. The issue also summarizes interviews from 30 veterans about ibogaine experiences at a 5-day treatment visit in Tijuana, Mexico.